Skip to main content
Universal Drugstore logo

Is Trelegy Ellipta Expensive?

In This Article

What Is Trelegy Ellipta and How Does It Work?

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is a once-daily inhaler that combines three different medications to treat chronic obstructive pulmonary disease (COPD) and asthma. This triple therapy approach targets multiple pathways in the lungs to provide comprehensive symptom control.

Shop Medications

,

The medication works through three distinct mechanisms. First, fluticasone furoate acts as an inhaled corticosteroid that reduces inflammation in the airways. Second, umeclidinium serves as a long-acting muscarinic antagonist that blocks M3 receptors, helping to relax and open the airways. Third, vilanterol functions as a long-acting beta2-agonist that stimulates beta2 receptors to further widen the breathing passages.

Unlike rescue inhalers used during breathing emergencies, Trelegy Ellipta is designed for maintenance treatment only. It helps prevent symptoms and breathing problems from occurring, but should never be used to treat sudden breathing difficulties.

Understanding Trelegy Ellipta Costs

Yes, Trelegy Ellipta is considered an expensive medication. The retail price for a one-month supply (one inhaler) of Trelegy Ellipta ranges between $800 and $900 without insurance.

For patients paying the full annual cost, expenses can reach over $10,800 per year at this price. However, insurance rebates and discounts often help patients reduce the cost.

The high price stems from several factors. Trelegy Ellipta remains under patent protection with no generic alternatives available in the United States. As a brand-name triple therapy, it represents newer technology compared to older, separate inhalers for each medication component.

Comparing Value and Cost Effectiveness

Independent research suggests Trelegy Ellipta may offer reasonable value despite its high upfront cost. The Institute for Clinical and Economic Review found that the medication provides incremental health benefits compared to generic alternatives when considering long-term outcomes.

Canadian cost-effectiveness studies show that single-inhaler triple therapy like Trelegy Ellipta reduces exacerbations and provides small gains in quality-adjusted life years. The cost-effectiveness ratios suggest the higher cost may be justified by improved health outcomes.

For many patients, using one inhaler instead of multiple separate devices can also improve medication adherence. Better adherence often leads to fewer emergency room visits and hospitalizations, potentially offsetting some of the medication’s higher cost.

Who Should Consider Trelegy Ellipta?

Healthcare providers typically prescribe Trelegy Ellipta for patients with moderate to severe COPD who continue experiencing symptoms despite using two-medication combinations. The medication is also approved for certain asthma patients who require combination therapy for adequate control.

Patients using multiple inhalers daily may benefit from switching to this single-device approach. The once-daily dosing schedule can simplify treatment regimens and reduce the chance of missing doses.

However, Trelegy Ellipta is not appropriate for everyone. Patients with sudden breathing problems, those allergic to any of the three components, or individuals with certain heart conditions may need alternative treatments.

Making Trelegy Ellipta More Affordable

Several strategies can help reduce the financial burden of Trelegy Ellipta. The manufacturer offers patient assistance programs and copay cards that may significantly lower out-of-pocket expenses.

Insurance coverage varies widely, so patients should work closely with their healthcare providers and insurance companies to understand their specific benefits. Some plans may require prior authorization or step therapy before covering Trelegy Ellipta.

For patients seeking cash-pay options or additional savings opportunities, Universal Drugstore provides a reliable platform to explore lower-cost access to medications. This can be particularly valuable for those without adequate insurance coverage or whose insurance does not cover the full cost.

Proper Use and What to Expect

Trelegy Ellipta comes in an Ellipta device designed for once-daily use. Patients take one inhalation at the same time each day, preferably in the morning.

Most patients begin noticing improvements in breathing within the first week of treatment, though maximum benefits may take several weeks to develop. The medication works continuously in the background to reduce inflammation and keep airways open.

Common side effects include upper respiratory tract infections, common cold symptoms, headache, changes in taste, and back pain. These effects are generally mild and manageable with proper inhaler technique and mouth rinsing after use.

Serious but Rare Side Effects

While most patients tolerate Trelegy Ellipta well, some serious side effects can occur in less than 1% of users. These include increased pneumonia risk in COPD patients, cardiovascular effects such as increased heart rate or blood pressure changes, and potential adrenal suppression with long-term use.

Eye problems, including glaucoma and cataracts, have been reported rarely with inhaled corticosteroids. Patients should have regular eye exams and report any vision changes to their healthcare providers immediately.

Severe allergic reactions are extremely rare but require immediate medical attention. Symptoms include difficulty breathing, swelling of the face or throat, and severe rash or hives.

The Bottom Line on Trelegy Ellipta

Trelegy Ellipta represents a significant investment in respiratory health, with costs that can challenge many patients’ budgets. However, the convenience of single-inhaler triple therapy and the potential for improved outcomes may justify the expense for appropriate candidates.

The medication’s effectiveness in reducing exacerbations and improving quality of life, combined with available patient assistance programs, makes it a viable option despite the high list price. Patients should discuss all available cost-saving options with their healthcare providers and explore resources like Universal Drugstore to find the most affordable access to their prescribed treatments.

Ultimately, the decision about whether Trelegy Ellipta is worth its cost depends on individual circumstances, insurance coverage, and how well other treatments have worked. Working closely with healthcare providers ensures patients receive the most appropriate and cost-effective treatment for their specific needs.

References

Related Conditions